Intravenous single dose iron infusio
Not Applicable
- Conditions
- Health Condition 1: D509- Iron deficiency anemia, unspecified
- Registration Number
- CTRI/2021/05/033579
- Lead Sponsor
- DST Chandigarh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Hemoglobin levels of >= 6 gm/dl - 9 gm/dl
2. Diagnosed case of Iron deficiency anemia.
3. Period of gestation between 20 to 36 weeks.
4. Singleton live pregnancy
Exclusion Criteria
1.Anemia other than iron deficiency anemia.
2.Known serious hypersensitivity to other parenteral iron products.
3.Patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.
4.Patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).
5.Chronic medical disorder
7.Antepartum hemorrhage
8.Anemia with heart failure
9. H/O Blood transfusion during current pregnancy.
11.COVID positive patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Increase in hemoglobin at 2 weeks, 6 weeks and at the time of delivery from the baseline hemoglobin. <br/ ><br>2. Increase in serum ferritin levels at 2 and 6 weeks from baseline value. <br/ ><br>3. Rise in reticulocyte count at 2 weeks. <br/ ><br>4.Side effects of intravenous iron Carboxymaltose <br/ ><br>Timepoint: At 2 weeks,6 weeks and on the day of delivery. <br/ ><br>
- Secondary Outcome Measures
Name Time Method Blood transfusion any time after complete dose of Intravenous ferric carboxymaltose injectionTimepoint: After complete dose of ferric carboxymaltose till delivery.